Vaxcyte DEF 14A: Executive Pay & Governance Details
Ticker: PCVX · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1649094
| Field | Detail |
|---|---|
| Company | Vaxcyte, Inc. (PCVX) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: PCVX
TL;DR
Vaxcyte's 2025 DEF 14A is out, detailing exec pay and board structure. Focus on equity awards and their valuation.
AI Summary
Vaxcyte, Inc. filed its DEF 14A on April 28, 2025, detailing executive compensation and corporate governance for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted, outstanding awards, and changes in fair value, as well as details on the company's board of directors and their compensation.
Why It Matters
This filing provides crucial insights into how Vaxcyte compensates its top executives and the structure of its board, which can influence strategic decisions and shareholder value.
Risk Assessment
Risk Level: medium — DEF 14A filings can reveal information about executive compensation and corporate governance that may impact investor confidence and stock performance.
Key Numbers
- 2024 — Fiscal Year End (The period covered by the compensation details in the filing.)
- 20250428 — Filing Date (The date Vaxcyte, Inc. submitted this DEF 14A to the SEC.)
Key Players & Entities
- Vaxcyte, Inc. (company) — Filer of the DEF 14A
- 20250428 (date) — Filing date of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for which compensation is reported
- SutroVax, Inc. (company) — Former name of Vaxcyte, Inc.
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit shareholder votes on important corporate matters, such as the election of directors and executive compensation.
When is the fiscal year end for Vaxcyte, Inc. as reported in this filing?
The fiscal year end for Vaxcyte, Inc. is December 31, 2024, as indicated by the reporting period.
What specific types of compensation information are typically found in a DEF 14A?
DEF 14A filings typically include details on executive compensation, including salary, bonuses, stock awards, option awards, and other benefits, as well as information on the company's board of directors and governance practices.
What was Vaxcyte, Inc.'s former company name?
Vaxcyte, Inc.'s former company name was SutroVax, Inc., with a date of name change on July 24, 2015.
What is the filing date of this DEF 14A for Vaxcyte, Inc.?
This DEF 14A filing for Vaxcyte, Inc. was filed on April 28, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Vaxcyte, Inc. (PCVX).